- Home
- EDRY vs UBX Comparison
EDRY vs UBX Comparison
Compare EDRY & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- UBX
- Stock Information
- Founded
- EDRY 2018
- UBX 2009
- Country
- EDRY Greece
- UBX United States
- Employees
- EDRY N/A
- UBX N/A
- Industry
- EDRY Marine Transportation
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- UBX Health Care
- Exchange
- EDRY Nasdaq
- UBX Nasdaq
- Market Cap
- EDRY 31.7M
- UBX 36.9M
- IPO Year
- EDRY N/A
- UBX 2018
- Fundamental
- Price
- EDRY $10.78
- UBX $1.80
- Analyst Decision
- EDRY
- UBX Strong Buy
- Analyst Count
- EDRY 0
- UBX 3
- Target Price
- EDRY N/A
- UBX $7.33
- AVG Volume (30 Days)
- EDRY 9.3K
- UBX 122.4K
- Earning Date
- EDRY 02-24-2025
- UBX 03-07-2025
- Dividend Yield
- EDRY N/A
- UBX N/A
- EPS Growth
- EDRY N/A
- UBX N/A
- EPS
- EDRY N/A
- UBX N/A
- Revenue
- EDRY $61,083,227.00
- UBX N/A
- Revenue This Year
- EDRY N/A
- UBX N/A
- Revenue Next Year
- EDRY $27.93
- UBX N/A
- P/E Ratio
- EDRY N/A
- UBX N/A
- Revenue Growth
- EDRY 28.35
- UBX N/A
- 52 Week Low
- EDRY $10.04
- UBX $0.94
- 52 Week High
- EDRY $24.84
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- EDRY 48.27
- UBX 49.99
- Support Level
- EDRY $10.51
- UBX $1.68
- Resistance Level
- EDRY $11.15
- UBX $1.98
- Average True Range (ATR)
- EDRY 0.31
- UBX 0.19
- MACD
- EDRY 0.03
- UBX 0.01
- Stochastic Oscillator
- EDRY 32.18
- UBX 63.98
Stock Price Comparison Chart: EDRY vs UBX
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.